Shares of 5100 XIZANG (01115) rose more than 5%. As of the time of writing, the stock was up 5.43%, trading at HK$0.485, with a turnover of HK$8.3873 million.
The increase follows a recent announcement from the company. On March 27, 2026, Kafuli Investment Limited, a wholly-owned subsidiary of the company, entered into a memorandum of cooperation with a research team led by Professor Feng Yibin from the School of Chinese Medicine at The University of Hong Kong. The agreement focuses on a teaching and research collaboration to clinically evaluate the efficacy of "5100" Tibet Glacier Mineral Water for patients with hyperuricemia. It also involves extended research into the potential mechanisms of the water's mineral components on uric acid metabolism and renal excretion.
As a representative enterprise in the natural drinking water sector in Tibet, the group is committed to exploring the functional health benefits of high-quality natural mineral water. This collaboration aims to integrate the traditional Chinese medicine concept of "medicinal and edible homology" with modern evidence-based medical research methods to conduct systematic health function studies on the "5100" product line. The initiative is expected to provide new scientific perspectives for integrating traditional Chinese medicine clinical treatments with daily health management.
The Board of Directors believes this cooperation will help enhance the scientific research foundation of the group's products and accumulate valuable experience for future product development and technological innovation within the broader health and wellness sector.
Comments